DUALITYBIO-B (09606) News

The report "Large Firms" by SWHY lists the forecasted potential symbols for inclusion in the Hong Kong Stock Connect for September (table).

Recently, SWHY released a report listing the potential candidates for inclusion in the Hong Kong Stock Connect for September: Ying'en Biological - B (09606.HK), Shandong Nanshan Aluminium (2610.HK), BLUE MOON GROUP (06993.HK), Caocao Mobility (02643.HK), Konka Optical (02276.HK), TIME INTERCON (01729.HK), Zhengli New Energy (03677.HK), Yunzhisheng (09678.HK), IFBH (06603.HK), ENVISION GREEN (01783.HK), and Yaojie Ankang - B (02617.HK), Zhou Liu Fu (0616.

AASTOCKSJul 9 12:27

Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk

WSJJul 3 16:34

Hong Kong stocks are moving unusually丨Ying'en Bio surged over 8%, with Institutions expecting that it may be included in the Hong Kong Stock Connect by early September.

On July 3, Glonghui reported that Hong En Biotechnology-B (9606.HK) saw an intraday surge, rising by as much as 8.4% to reach 258 Hong Kong dollars. In terms of news, the Hang Seng Index Company will announce the review results of the Hang Seng Index series for the second quarter of 2025 on August 22 (Friday), and changes to the constituent stocks will take effect on September 8 (Monday). HTSC issued a report stating that the Shanghai and Shenzhen exchanges will correspondingly adjust the investment scope of Hong Kong Stock Connect, and it is expected that 19 Hong Kong stocks, including Hong En Biotechnology, may be included in the Hong Kong Stock Connect scope.

Gelonghui FinanceJul 3 11:07

HTSC expects that 19 stocks may be included in the Hong Kong Stock Connect at the beginning of September, including coconut water company IFBH and Zhou Liu Fu.

If coconut water company IFBH (06603.HK) opened 2% higher this morning (2nd) and continued to rise, the latest price is 42.65 yuan, up nearly 8%, with a transaction volume of 0.258 billion yuan. However, Zhou Liu Fu (06168.HK) fell back after reaching a peak, currently down 3.4% at 46.8 yuan. HTSC published a report indicating that as of June 30, the Hang Seng Composite Index semi-annual review period has ended, and the adjustment list is expected to be announced after the market closes on August 22 this year. All changes will be implemented after the market closes on September 5 (Friday) and will take effect from September 8 (Monday), at which time the Shanghai and Shenzhen Exchanges will accordingly adjust the Hong Kong Stock Connect.

AASTOCKSJul 2 11:49

Express News | The surge in subscription multiples is frequently seen; the Hong Kong stock market is hot for new listings.

BreakingsJun 16 02:43

This week's Hong Kong stock market bulls | The escalation of the situation in the Middle East has driven oil and gas stocks to surge, with SINOPEC SSC rising 25% on Friday; pharmaceutical stocks are performing well, with LUYE PHARMA increasing over 33% du

This week, the Hang Seng Index has risen by 0.42%, closing at 23,892.56 points; during the same period, the Hang Seng TECH Index has decreased by 0.89%, closing at 5,239.71 points; the Hang Seng China Enterprises Index has risen by 0.3%, closing at 8,655.33 points.

Futu NewsJun 14 11:46

Yingen Biotech (09606.HK) presented the results of two studies at the 2025 American Society of Clinical Oncology oral presentations.

Yingen Biotechnology-B (09606.HK) has issued a statement regarding recent fluctuations in stock price and Volume. The company published a news article on its website on June 5, detailing two research results presented in a verbal report on ADC candidates HER3 ADC DB-1310 and B7H3 ADC DB-1311/BNT324 at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. Preliminary data indicate early clinical activity and controllable safety characteristics, with a low rate of treatment discontinuation. The most common adverse events are gastrointestinal and hematologic toxicity, requiring clinical management.

AASTOCKSJun 10 23:06

The stock price of Mingen Biotech-B (09606.HK) is experiencing unusual fluctuations. The information contained in the news article does not constitute insider information.

On June 10, Gelonghui reported that the Board of Directors of Wintech Bio-B (09606.HK) has learned about the recent fluctuations in the Fill Price and Volume of the company's shares on the Hong Kong Stock Exchange on June 9 and June 10, 2025. The Board also noted that on June 5, 2025, the company published a news article on its website regarding the preliminary data of its ADC candidate drug presented in a verbal report at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. After making all reasonable inquiries regarding the company in this context, the Board confirms that (i) regarding...

Gelonghui FinanceJun 10 19:27

Hong Kong stock midday review | The three major indices are mixed, with the Hang Seng Index up 0.33%; airline and pharmaceutical stocks performed well, with China Eastern Airlines rising nearly 5% and 3SBIO rising over 11%.

The Network Technology stocks are adjusting, Bilibili-W rose by 1.93%, MEITUAN-W fell by 1.48%; sports equipment stocks are all rising, 361 DEGREES rose by 4.20%, LI NING rose by 2.93%; the dining stocks are all going up, JIUMAOJIU rose by 7.11%, and Xiaocaiyuan rose by 3.95%.

Futu NewsJun 10 12:15

Hong Kong Stock Market Afternoon Review | Hang Seng Index rose 0.33% in the morning session, with the banking sector continuing its upward trend.

Insurance funds continue to increase their shareholding in China Mainland Banking. Institutions claim that there is still significant room for valuation recovery in Hong Kong Bank stocks.

Zhitong FinanceJun 10 12:00

Ying'en Biological-B (09606.HK) is covered for the first time: a leading player in the ADC Industry, expected to continue growing into China's 'first Santen'.

Core pipelines possess international competitiveness, and the clinical development process secures a competitive advantage. Mineng Bio was established in 2019, focusing on developing next-generation ADC innovative drugs for patients with cancer and autoimmune diseases. The company has established 12 products.

HAITONG INT'LJun 10 07:17

Hong Kong Stock Midday Review | All three major indices rose, with the Hang Seng Index returning above 24,000 points; new consumption and CNI Biomedicine Index stocks performed strongly, with Bloks Group rising over 18% and WUXI BIO rising over 5%.

Network Technology stocks rose, KUAISHOU-W increased by 5.58%, and MEITUAN-W rose by 5.15%; biotechnology stocks generally rose, GENSCRIPT BIO increased by 14.09%, and Cloud-top New Material rose by 11.33%; Nonferrous Metals stocks weakened, ZHAOJIN MINING fell by 6.02%, and SD GOLD dropped by 5.59%.

Futu NewsJun 9 12:15

[Brokerage Focus] CMB International initially rates ImmunoPrecise Bio (09606) as Buy, noting that it has a rich pipeline of self-developed ADCs.

King Wu Finance | According to research reports from CMB International, InnoCare Pharma (09606) has a rich pipeline of self-developed ADCs: DB-1303/BNT323 (HER2 ADC) with its first indication being HER2-expressing endometrial cancer (EC), and management expects to apply for accelerated approval from the FDA as early as this year; DB-1311/BNT324 (B7-H3 ADC) is being developed for single-agent and combination treatments for small cell lung cancer (SCLC, including monotherapy and combination immunotherapy); DB-1310 (HER3 ADC) utilizes a differentiated development approach.

King Wu Financial NewsJun 6 13:13 · Ratings

DUALITYBIO(9606.HK):EMERGING AS A GLOBAL LEADER IN ADC INNOVATION WITH NEXT-GEN PLATFORMS AND STRATEGIC COLLABORATIONS

Jun 6 11:22

[Hot Industry] Hong Kong stocks in the CNI Biomedicine Index have erupted again. The medical insurance negotiations in the second half of the year may catalyze valuation recovery.

King Wu Financial News | Today, the Hong Kong stock market's CNI Biomedicine Index performed remarkably. By the close, the stock prices of companies such as INNOVENT BIO (01801), ZAI LAB (09688), Kelun Biotech (06990), and CSPC PHARMA (01093) significantly rose, with increases reaching 14.14%, 12.22%, 5.53%, and 4.14% respectively. Hengrui Pharmaceuticals (01276), HANSOH PHARMA (03692), Yinger Biotech (09606), and AKESO (09926) also followed suit. Notably, since the beginning of the year, REMEGEN (09995) and 3SBIO (015...

Jingu Finance NewsJun 4 16:51

Hong Kong stock market movement | InnoCare Pharma-B (09606) rose over 3%, revealing HER3 ADC clinical data for the first time at the 2025 ASCO conference.

Ying En Biological-B (09606) rose over 3%. As of the time of writing, it increased by 3.17%, priced at 208.4 Hong Kong dollars, with a transaction amount of 22.258 million Hong Kong dollars.

Zhitong FinanceMay 28 10:30

Both have entered the Hong Kong Stock Connect! Horizon Robotics and Xiamen Jihong Package Technology have seen a surge. Which other companies are likely to qualify for the Hong Kong Stock Connect?

Generally speaking, the Hong Kong stock market has liquidity issues, particularly small-cap companies that can easily fall into long-term liquidity shortages. Entering the Hong Kong Stock Connect can enable them to gain support from mainland funds, significantly enhancing their liquidity.

Futu NewsMay 27 16:14

The "A+H" profit effect is prominent! Contemporary Amperex Technology and Hengrui Pharmaceuticals are leading, with the three essentials for a bull stock: top pricing, oversubscription, and a significant price increase at the opening.

There are three reasons why Hengrui Pharmaceuticals has been able to perform so well: first, the company's quality is quite good; second, since 2025, a "bull market for innovative drugs" has unfolded in the Hong Kong stock market; third, the profitability effect of Hong Kong stock IPOs continues to stand out.

Securities TimesMay 23 11:32

【Brokerage Focus】China Securities Co.,Ltd.: The implementation of Trump's "Most Favored Nation" policy on drug prices needs to be verified, and its short-term impact on the Global pharmaceutical market is not significant.

Jinwu Financial News | China Securities Co.,Ltd. Research Reports indicate that the high pharmaceutical pricing system in the USA leads to a higher proportion of Medical expenses relative to GDP. Pharmaceutical prices are mainly influenced by market mechanisms, and the pricing system involves multiple stakeholders, which collectively drive up drug prices, while the share of pharmaceutical spending that flows to non-manufacturers continues to increase. In response, Trump proposed the "Most-Favored-Nation" drug pricing policy during his previous term, aimed at reducing drug prices in the USA. On May 12, 2025, Trump once again proposed the "Most-Favored-Nation" drug pricing policy, but the current policy remains unclear and uncertain, and its implementation is expected to require verification and a longer time frame.

Jinwu Financial NewsMay 19 08:34

Yimeng Biological-B (09606.HK): Price stabilization actions and the end of the price stabilization period.

Glory Holdings announced on May 12 that the stabilization period for the global offering of Yingen Bio-B (09606.HK) will end on May 10, 2025 (Saturday), which is 30 days after the deadline for submitting applications for the Hong Kong public offering. The stabilization actions conducted by the stabilization agent Morgan Stanley Asia Limited or its affiliates or any person acting on its behalf during the stabilization period are listed as follows: (1) A total of 2.5998 million shares were allotted in the international offering, accounting for about 15% of the total number of shares available for subscription under the global offering (after taking into account the adjustment of the offering volume).

Gelonghui FinanceMay 12 08:21